![]() Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s other filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site ( Opens a new window). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. ![]() Although these statements are based on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and you should not place undue reliance on them. Avsola 100mg vial Inflectra 100mg vial Renflexis 100mg vial Other (please specify): Dose and Quantity: Duration of therapy: J-Code: Frequency of administration. By their nature, forward-looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995. Call a Janssen CarePath Care Coordinator at 877-CarePath (87), Monday-Friday, 8:00 AM to 8:00 PM ET. The Organon Patient Assistance Program provides certain Organon medicines free of charge to eligible. Janssen CarePath provides additional support to your patients, including patient education, web-based resources, and personalized reminders. TYSABRI ActiveAccess™ Financial Program – ĪstraZeneca Patient Assistance Programs – Īzasan (Azathioprine from Salix Pharmaceuticals, Inc.Any statements set forth on this website that are not historical facts are considered “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. THE ORGANON PATIENT ASSISTANCE PROGRAM FOR RENFLEXIS. Janssen Prescription Assistance (Stelara) – Janssen Prescription Assistance (Simponi) – The Merck Access Program for Renflexis (infliximab-abda) – Maximum co-pay assistance program benefit per calendar year is determined by Organon. Once enrolled, eligible, privately insured patients pay the first 5 of their co-pay per infusion. For eligible underinsured or uninsured patients. If you are unable to confirm your eligibility or have additional questions, call XELSOURCE at 1-84. Renflexis (Infliximab-abda – biosimilar of infliximab) The Organon Co-pay Assistance Program offers assistance to eligible patients who need help affording the out-of-pocket costs for RENFLEXIS. The Organon Co-pay Assistance Program offers assistance to eligible, privately insured patients who need help affording the out-of-pocket costs for RENFLEXIS. Our Co-Pay Savings Program may reduce out-of-pocket cost for eligible, commercially insured patients who have been prescribed XELJANZ. Janssen Prescription Assistance (Remicade) – Pfizer enCompass Program for Inflectra (infliximab-dyyb) – Because LM had a commercial insurance plan, she qualified for the manufacturer-sponsored copay assistance program. Inflectra (Infliximab-dyyb – biosimilar of infliximab) Here are some patient assistance programs for commonly used medications, offered by the pharmaceutical companies that make them: Many Inflammatory Bowel Disease patients struggle to cover the costs of their medications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |